

## <sup>23</sup>**Abstract**



32 conducted replication analyses leveraging two other independent human plasma

33 proteomics datasets, encompassing 7,213 participants from the Atherosclerosis Risk

34 in Communities (ARIC) study and 3,301 individuals from the INTERVAL study.

36 We identified 94 genes that are consistent with being causal in CVD, acting via their 37 cis-regulated plasma protein abundance. 34 of 45 genes were replicated in at least one 38 of the replication datasets. 41 of the 94 genes are novel genes not implicated in 39 original GWAS. 91.48% (86/94) proteins are category-specific, only two proteins <sup>40</sup>(ABO, PROCR) were associated with diseases in all three CVD categories. <sup>41</sup>Longitudinal analysis revealed that 37 proteins exhibit stable expression in plasma. In 42 addition, PBMC scRNA-seq data analysis showed that 23 of the 94 genes were stably 43 expressed in CD14+ monocytes, implicating their potential utility as biomarkers for <sup>44</sup>CVD disease status. Drug repurposing analyses showed that 39 drugs targeting 23

- 45 genes for treating diseases from other systems might be considered in further research.
- 
- 47 In conclusion, our findings provide new insights into the pathogenic mechanisms of
- <sup>48</sup>CVD and offering promising targets for further mechanistic and therapeutic studies.
- 
- 50 Keywords: CVD; Human blood plasma proteomes; Causal proteins; PWAS
- 
- 52

## <sup>53</sup>**Introduction**



61

62 Proteins, as the final products of gene expression, are the main functional components 63 of biological processes<sup>6</sup>. In addition, most therapeutic agents target proteins<sup>7</sup>. <sup>64</sup>Therefore, understanding their relationship with diseases is crucial for effective 65 treatments<sup>8-11</sup>. However, direct observational studies linking protein abundance to 66 phenotypes can be confounded or represent reverse causation<sup>12</sup>. Proteome-wide 67 association study (PWAS) is a powerful strategy to solve this problem. It uses single-68 nucleotide polymorphisms (SNPs) to genetically impute proteins and relate them to <sup>69</sup>genome wide association study (GWAS) summary statistics of a trait to provide 70 evidence of causality<sup>13, 14</sup>. The genetic models are restricted to the cis-region of the <sup>71</sup>protein, reducing the risk of confounding by horizontal pleiotropy (independent of the 72 protein). Further summary data-based Mendelian randomization  $(SMR)^{15}$  or 73 colocalization analyses<sup>16</sup> can be used to identify genes contribute to disease 74 pathogenesis through modulating protein abundance. This integrative analytical

<sup>75</sup>approach has been employed to identify novel potential therapeutic targets for 76 neurological disorders<sup>13, 14, 17-19</sup> using brain proteomics data. However, PWAS for 77 CVD is still limited.

<sup>79</sup>Using plasma proteomics data of the largest cohort to date (53,022 individuals from 80 the UK Biobank Pharma Proteomics Project (UKB-PPP) project<sup>20</sup>), we present here 81 the first PWAS for multiple CVDs. The study design is shown in Figure 1. We applied 82 the above analytic approaches to the discovery dataset consisting of human plasma 83 proteomic and genetic data from UKB-PPP<sup>20</sup> and the GWAS of 26 CVDs spanning 3 84 categories (16 cardiac diseases,  $N = 234,829 \sim 1,030,836$ ; 5 venous diseases, N = 85 388,830~484,598; 5 cerebrovascular diseases, N =  $484,598 \sim 1,308,460$ <sup>21-26</sup>. 86 Additionally, we conducted replication analyses leveraging two independent human 87 plasma proteomics datasets<sup>27, 28</sup>, encompassing 7,213 participants from the <sup>88</sup>Atherosclerosis Risk in Communities (ARIC) study and 3,301 individuals from the <sup>89</sup>INTERVAL study, to ensure robustness and reproducibility. For functional 90 interpretation of the identified proteins, enrichment analyses were performed to detect 91 the pathways associated with CVD. Longitudinal stability analysis at plasma and cell-92 type level was used to assess the expression stability of the proteins. We also 93 pharmacologically annotate the proteins of interest with approved drugs to assess their 94 feasibility as treatment targets.

95

<sup>96</sup>**Results** 

## <sup>97</sup>*Discovery PWAS of multiple CVDs*

98 We generated the human blood plasma proteome model based on  $53,022 \text{ UKB-PPP}^{20}$ 99 participants. The initial proteomes data include total 2,923 proteins. After quality 100 control, 1,715 proteins with significant SNP-based heritability ( $P < 0.05$ ,  $h^2 > 0$ ), were 101 used for PWAS. The correlation  $R^2$  between the model's predictive power and 102 heritability for each gene was 0.88 (Supplementary Figure S1), supporting the 103 accuracy of our protein estimation model.

104

105 The plasma proteome model results were integrated with the 26 CVD GWAS data 106 using the FUSION pipeline<sup>29</sup>. Detail information of the 26 GWAS datasets is shown 107 in Supplementary Table S1. We performed genetic correlation analysis and the results <sup>108</sup>showed that diseases belong to the same category are usually with higher correlation 109 (Supplementary Figure S2).

<sup>111</sup>As shown in Supplementary Table S2, we identified 341 significant protein-CVD 112 pairs of associations after multiple testing corrections  $(P < 2.92 \times 10^{-5}, 0.05/1,715)$ 113 proteins) (Fig 2A). Among these associations, 87 genes are located within 1 Mb of 114 each other. With the goal of identifying multiple independent associations, we 115 performed conditional analyses using a regression with summary statistics approach  $2^7$ . <sup>116</sup>27 pairs of associations no longer significant associations were removed <sup>117</sup>(Supplementary Table S3). Finally, we obtained 314 independent and significant <sup>118</sup>PWAS association signals, including 155 unique proteins associated with CVD. The



139

## <sup>140</sup>*Causal-analysis of the proteins identified by PWAS*



156 were remained for subsequent analysis (Fig 3A, Supplementary Table S5).

158 Combining evidence for replication and results of causality tests, 45 of 94 causal 159 proteins were detected in the at least one of replication proteomic datasets. 75.56% (34/45) proteins were found to be with evidence of both replication and causality (Table 1). There were 28 proteins replicated in the ARIC dataset and 21 proteins 162 replicated in the INTERVAL dataset. In particular, 15 proteins were replicated in both

163 datasets. For example, ABO, F10, IL6R and PROC.

164

#### <sup>165</sup>*Common proteins associated with diseases in three CVD categories*

- <sup>166</sup>91.49% (86/94) proteins were identified in only one disease category (Fig 3B). Only 2
- 167 proteins (ABO, PROCR) were associated with diseases in all three CVD categories.
- <sup>168</sup>As shown in Figure 3A, ABO showed significant positive associations with multiple
- 169 diseases from the three categories. PROCR was negatively associated with 2 cardiac
- 170 diseases and 1 cerebrovascular disease, and positively associated with 2 venous
- 171 diseases. The inconsistency in association direction might because PROCR is linked
- 172 to anti-inflammatory and anticoagulant functions<sup>30</sup>.
- 173

#### <sup>174</sup>*Novelty of the CVD causal genes*

175 To assess the novelty of the 94 potentially causal genes, we checked the lowest p-176 values for the SNPs within 2 Mb window of these genes using the summary statistics 177 from the CVD GWAS. We found that 41 genes were not located within 2 Mb of a 178 significant GWAS signal ( $P < 5 \times 10^{-8}$ ), suggesting that these 41 genes are novel 179 genes not implicated in the original GWAS (Fig 3C). 25 of the novel genes were have 180 not been detected in other CVD GWAS either. For example, PROC was found to be 181 associated with venous thromboembolism (Fig 3D top) and COMT was found to be 182 associated with three cardiac diseases (hypertension, statin medication and angina 183 pectoris; Supplementary Figure S3). All 26 CVD GWAS data didn't detect their 184 association with CVD diseases. The rest 16 novel genes were not implicated in the



192

### <sup>193</sup>*Gene ontology enrichment analysis*

<sup>194</sup>To further elucidate the molecular mechanisms underlying the 94 identified proteins, 195 we carried out a non-redundant gene ontology (GO) biological processes enrichment 196 analysis using WebGestalt  $2024^{31}$ ,  $32$ . The results (Fig 4A) showed that genes 197 associated with cardiac disease enriched in 12 pathways.  $58.33\%$  (7/12) of these 198 pathways belong to three categories (immunity/inflammation, lipid-related process, 199 and vessel/blood-related process). Genes associated with venous diseases were found 200 to be significantly enriched in 5 biological pathways, and three of them belong to the 201 vessel/blood-related process, particularly the coagulation process. No significant 202 pathway was detected for the genes associated with cerebrovascular disease due to the 203 limited number of genes.

204

## <sup>205</sup>*Protein-protein interactions (PPI) network analysis*

<sup>206</sup>To investigate the connectivity for the 94 proteins, we performed network-based



## *Mouse phenotypic annotation of potential causal genes.*

We further evaluated whether 94 proteins were associated with CVD-related 222 phenotype in mouse using the Mouse Genome Informatics (MGI) database<sup>34</sup>. We 223 performed phenotype enrichment analysis using the Fisher's exact test. Consistent 224 with the pathway enrichment and network analysis results, mutations in genes 225 associated with cardiac diseases are enriched in phenotypes related to 226 immunity/inflammation, lipid-related process, and vessel/blood-related process (Fig 4C). Mutations in genes associated with venous disease are enriched in phenotypes 228 related to vessel/blood-related process (Fig  $4C$ ). These results further support the

229 involvement of the identified proteins in CVD pathogenesis.

## <sup>231</sup>*Evaluate longitudinal stability at protein and single-cell level*

<sup>232</sup>To evaluate the expression stability of the 94 proteins, we performed longitudinal <sup>233</sup>analysis using data using plasma proteomics data and peripheral blood mononuclear 234 cells (PBMC) single cell RNA-seq (scRNA-seq) data from GEO dataset GSE190992.

236 The plasma proteomics data were collected from 6 healthy, non-smoking Caucasian <sup>237</sup>donors over a 10-week period. 44 of the 94 proteins were detected in this dataset. <sup>238</sup>Among them, 84.09% (37/44) proteins exhibit stable expression in plasma (median 239 coefficient of variation  $< 10\%$ , Fig4 D left). Fluctuations in the plasma levels of these 240 proteins might serve as potential markers of disease status.

242 The PBMC scRNA-seq data were collected weekly from four donors over the course 243 of six weeks. We found 24 genes exhibited stable expression in at least one cell type 244 (median coefficient of variation  $< 10\%$  in at least one cell type across all donors. Fig4 <sup>245</sup>D right). Notably, 23 of the 24 genes stably expressed in CD14+ monocytes. As per 246 previous studies, monocytes play a crucial role in both local ischemia and 247 inflammatory responses, which are closely linked to the development of 248 cardiovascular diseases  $35-37$ .

249

## <sup>250</sup>*Cell-type specific expression of the CVD causal genes*



259

## <sup>260</sup>*Drug repurposing analyses identified potential therapeutic targets for CVD*

261 To investigate the potential drug target genes, we construct a gene-drug-disease 262 network (Fig4 D). The results showed that 25 of the 94 proteins are the targets of 53 263 drugs with completed or currently undergoing clinical trials (Supplementary Table 10). 264 14 drugs have already been used for treating circulatory system disorders. For 265 example, Drotrecogin alfa targeting *F2*, *PROCR* and *PROS1* are currently one of the 266 efficacious treatments for managing cerebrovascular ischemic events<sup>38</sup>. The rest 39 267 drugs for treating diseases from other systems might be considered in further drug 268 repurposing research. For example, Menadione targeting PROC are currently used for 269 treating vitamin K deficiency and prostate cancer.

270

<sup>271</sup>**Discussion** 

272 In this study, we integrated data from 26 CVD GWAS along with three large-scale 273 human plasma protein datasets to conduct a comprehensive PWAS analysis. 274 Collectively, we identified 186 significant independent protein-disease association 275 pairs, involving 94 unique proteins associated with CVD. Among these proteins, 41 276 proteins are novel proteins not implicated in original GWAS. We also elucidated 277 potential biological mechanisms underlying CVD and provided potential new targets 278 for CVD drug development.

279

280 The PWAS analysis identified 96 genes that are consistent with being causal in CVD, 281 including 41 novel genes not implicated in original GWAS. For example, PROC was 282 newly found to be associated with venous thromboembolism. PROC is a vitamin K-<sup>283</sup>dependent enzyme that plays a crucial role in regulating human thrombosis and 284 hemostasis<sup>39</sup>. Consist with our results, previous studies have demonstrated that 285 reduced PROC levels in plasma can be used as a marker of increased risk of venous 286 thrombosis $40, 41$ . In the PPI network, we also demonstrated that PROC, together with 287 coagulation factors such as F2 and F10, forms a venous-related network. Longitudinal 288 stability analysis showed that this protein is stably expressed in blood plasma. 289 Currently, two drugs (Menadione and Cupric Chloride) targeting PROC have passed 290 clinical trials for the treatment of conditions such as fungal infections, prostate cancer, 291. and vitamin K deficiency<sup>42</sup>. Further studies are needed to explore the potential of 292 these drugs for treating venous thromboembolism.

<sup>294</sup>91.49% (86/94) of the identified proteins are category-specific, suggesting that the 295 underlying pathogenesis mechanisms of the three disease categories are different. 296 Only two proteins (ABO and PROCR) were associated with diseases in all three CVD 297 categories. ABO was found to be positively associated with multiple cardiovascular 298 diseases. Consistently, epidemiological studies have reported that ABO is associated 299 with a wide range of diseases, including cardiovascular ailments, malignancies, and  $300$  infectious conditions<sup>43,44</sup>. PROCR is positively associated with venous disorders but 301 negatively associated with stroke and coronary artery disease. PROCR is a receptor 302 for activated protein C, which is a serine protease activated by and involved in the <sup>303</sup>blood coagulation pathway. Consistent with our results, GWAS studies have shown 304 that the minor G allele of rs867186 at this gene is correlated with a higher risk of 305 venous thromboembolism<sup>45, 46</sup> but a lower risk of  $CAD^{47, 48}$ . A previous study<sup>30</sup> has 306 shown that PROCR linked to CAD through anti-inflammatory mechanisms and to 307 VTE through pro-thrombotic mechanisms.

308

<sup>309</sup>The longitudinal stability analysis showed that 37 of the 44 detected proteins (84.09%) 310 exhibit stable expression in plasma, suggesting that they might serve as potential 311 markers of disease status. In addition, PBMC scRNA data analysis identified 24 genes 312 exhibited stable expression in at least one cell type and 23 of the 24 genes stably 313 expressed in CD14+ monocytes, highlighting the important role of CD14+ monocytes 314 in CVD development. Consistently, previous studies have associated increased 315 frequency of the CD14+ monocytes clinical CVD events and plaque vulnerability<sup>49, 50</sup>.

316 Monocyte density of CD14 was found to be higher in patients with moderate  $\Box$  severe 317 heart failure in comparison with normal or mild LV impairment  $51, 52$ . These results 318 suggested that CD14+ monocytes might be used as markers for CVD. 320 Our study has several limitations. First, since the current available proteomics and <sup>321</sup>GWAS are mainly derived from European populations, our results are mainly 322 applicable to the European population. Second, we focused on cis-regulatory elements 323 when constructing models to assess protein influences. This is a common choice for 324 current researchers, because the current sample size of proteomics may not be 325 sufficient to detect the trans effect. With larger scale data available in future, models 326 considering both cis and trans effects can be constructed.

328 In summary, using the largest available proteomics data from UKB-PPP projects (a 329 total of 1,715 inheritable proteins from 53,202 individuals), we performed a PWAS 330 study for 26 CVDs. We identified 94 genes that contribute to CVD pathogenesis 331 through modulating their plasma protein abundance. These genes may serve as 332 potential targets for future mechanistic and therapeutic studies aimed at finding <sup>333</sup>effective treatments for CVD.

334

<sup>335</sup>**Methods** 

### <sup>336</sup>**Human plasma proteomic and genetic data in UKB.**

<sup>337</sup>We generated the human blood plasma proteome models from 53,022 participants of



357 Following the preprocessing of both genotype and protein datasets, we adopted the FUSION software to train the proteome model and we only consider the subset 359 comprising 1,190,321 SNPs from the HapMap3 project . SNPs situated up to 500 kb

360 away from either end of genes were defined as cis-SNPs. The model further <sup>361</sup>incorporated adjustments for protein expression based on gender and age as covariates 362 to refine the association analysis and account for potential confounding variables.

#### <sup>364</sup>**CVD GWAS summary association statistics**

365 Our GWAS data mainly comes from the GWAS catalog <sup>22 25 21, 23, 24, 26</sup> and FinnGen<sup>57</sup> 366 database. In accordance with the ICD-10 standard of circulatory disorders, we 367 selected GWAS studies involving a minimum of 5,000 cases. When multiple studies 368 of the same condition were identified, we opted for those with the largest sample sizes. <sup>369</sup>This stringent selection procedure resulted in a final cohort of 26 unique GWAS for 370 our investigation. Based on the distinct pathophysiological mechanisms, we 371 categorized the diseases into cardiac diseases, venous disease, and cerebrovascular 372 disease.

## <sup>374</sup>**Statistical approach**

<sup>375</sup>*Proteome-wide association studies (PWAS)*. We used the standard processes in the 376 FUSION software<sup>29</sup> to construct protein models and incorporate GWAS data for our 377 PWAS analysis. After applying the previously outlined quality control measures to  $378$  screen the sample and genotype data, we utilized GCTA software<sup>58</sup> to estimate the 379 SNP-based heritability for individual proteins. To expedite calculations, a random 380 subset of approximately 10,000 individuals was selected from the full cohort for each 381 protein's heritability estimation. From the analysis of 2,923 proteins, 1,715 displayed

382 statistically significant heritability ( $h^2 > 0$ , p < 0.05). We then employed the FUSION <sup>383</sup>software to estimate the impact of SNPs on protein abundance using multiple 384 predictive models (top1, lasso, enet)<sup>29</sup> and select the most predictive model as the 385 final predictor. Finally, we obtained a total of 1,715 distinct protein models encoded <sup>386</sup>by different genes and we applied the Bonferroni correction for multiple testing. 387 Consequently, proteins with a P-value threshold of  $2.92\times10^{-5}$  (0.05/1,715) were 388 deemed statistically significant in our discovery PWAS analysis.

389

<sup>390</sup>We then performed the replication PWAS analysis in two other publicly available data 391 sets. The modeling methodologies for these datasets have been documented in prior 392 research, the Atherosclerosis Risk in Communities (ARIC) study dataset included 393 4,483 protein measurements from 7,213 European participants  $27$ , while the 394 INTERVAL study retained information on 3,170 proteins for  $3,301$  individuals  $^{28}$ . 395 Subsequent to the heritability filtering phase, an ensemble of 2,379 proteins (1,348 in <sup>396</sup>ARIC and 1,031 in INTERVAL) was selected for incorporation into our replication 397 verification.

398

<sup>399</sup>*Causal analysis.* We adopted two independent frameworks to rigorously ascertain the 400 causal inference of the proteins implicated in our PWAS findings. For the Bayesian 401 colocalization analysis  $16$ , we employed the COLOC module embedded within the <sup>402</sup>FUSION software suite. The COLOC tool operates by estimating the posterior <sup>403</sup>probability indicating that the same causal variant underlies both GWAS and pQTL.



### **PPI and GO enrichment**

417 For the investigation of causal genes implicated in three diseases, we employed the 418 STRING database to perform an extensive network analysis. The Markov cluster (MCL) algorithm was used with the following parameters: inflation parameter—1.5. 420 Subsequently, the derived network was refined and visually optimized utilizing 421 Cytoscape software. In this visualization, node size corresponds to the degree of 422 connectivity for each gene, indicative of its interaction frequency within the network, 423 while distinct colors denote different gene categories, facilitating categorical 424 distinction and interpretation. Additionally, we conducted functional enrichment 425 analysis for causal genes pertinent in three categories diseases using the WebGestalt

426 online platform, focusing on the GO BP pathways. We select the pathways with  $P <$ 

427 0.05 (with FDR adjusted) and number of overlap genes  $> 3$  as the significant result.

#### <sup>429</sup>*Longitudinal Data Stability Analysis*

430 We conducted a longitudinal analysis utilizing the data set GSE190992 from the Gene 431 Expression Omnibus (GEO) database  $^{60}$ . Specific details regarding the data collection 432 methodology and information have been reported in detail in a previous publication. <sup>433</sup>The data encompass proteomics measurements over a 10-week period for 6 healthy 434 donors, as well as single-cell data collected over a six-week period for 4 of these 435 donors. For each donor, we calculated the coefficient of variation (CV) for each gene 436 at both the proteome and single-cell levels as a measure of stability ( $CV = standard$ ) 437 deviation / mean  $\times$  100%). We selected thresholds of 10% as criteria for stable gene <sup>438</sup>expression in proteome data and single-cell data, respectively. These genes that 439 exhibit stable expression in plasma, along with the associated cell types, can be 440 considered as more reliable biomarkers for early screening and prediction of CVD.

#### <sup>442</sup>*Cell-type specific expression of the CVD causal genes*

<sup>443</sup>We utilized scRNA-seq data from 11 healthy donors sourced from the GEO database <sup>444</sup>(GSE244515). During the preprocessing phase, we filtered out cells that expressed 445 less than 200 genes or had a mitochondrial gene content exceeding 15%. For cell type 446 annotation, we normalized the count matrices using the LogNormalize method with a 447 scaling factor of 10,000, which also helped in identifying variable features. To align



457

## <sup>458</sup>**Mouse genome informatics and Drug analysis**

459 MGI database  $34$  serves as a global repository for murine research, offering a 460 comprehensive integration of genetic, genomic, and biological information. This 461 platform fosters investigations into human health and disease by facilitating insights 462 garnered from mouse models and we demonstrated many of the gene deletion mouse 463 models exhibit phenotypes associated with circulatory system disease. We enriched 464 the mouse phenotype using the Fisher's exact test method, and retained phenotypes 465 with more than three overlap genes,  $P < 0.05$  (with FDR adjusted) and OR  $> 1$ . <sup>466</sup>Furthermore, we constructed a gene-drug-disease interaction network by integrating 467 gene-drug associations from the DrugBank  $<sup>61</sup>$  database and drug-disease relationships</sup> 468 from the Therapeutic Target Database (TTD)  $^{62}$ . Our network focused exclusively on 469 drugs with approved clinical efficacy and excluding those with discontinued

470 development at any stage.

471

#### <sup>472</sup>**Code availability**

473 All software and datasets in our study are publicly available online.

## <sup>475</sup>**Acknowledgments**

- 476 This research has been conducted using the UK biobank resource under application
- 477 number 46387.

478

## <sup>479</sup>**Funding**

- 480 This work was supported by the National Natural Science Foundation of China
- <sup>481</sup>(32370653, and 82372458); Innovation Capability Support Program of Shaanxi
- <sup>482</sup>Province (2022TD-44); Key Research and Development Project of Shaanxi Province
- <sup>483</sup>(2022GXLH-01-22), and the Fundamental Research Funds for the Central
- <sup>484</sup>Universities. This study was also supported by the High-Performance Computing

485 Platform and Instrument Analysis Center of Xi'an Jiaotong University.

486

### <sup>487</sup>**Data and Resource Availability**

- 488 The GWAS summary data of CVD we used in this article were available from GWAS
- 489 catalog (https://www.ebi.ac.uk/gwas/downloads/summary-statistics) and FinnGen
- <sup>490</sup>study (https://finngen.gitbook.io/documentation/data-download). Download links for
- 491 all datasets are provided in Table S1.

492

## <sup>493</sup>**Author Contributions**

- 494 J.-H.W. and S.-S.D. designed this project. J.-H.W., A.-H.W., and C.-R.W. conducted
- 495 the computational work. J.-H.W. wrote the manuscript. S.-S.D. and A-H.W. revised
- 496 the manuscript. J.-H.W., H-A.W. and S.-S.D. summarized the tables and figures. R.-
- 497 J.Z., W.S., H.W., K.Y, T.-P.Z., X.Y. M. and S-S.L. collected the public data. Y.G. and
- 498 T.-L.Y. supported and supervised this project.

#### <sup>500</sup>**Ethical approval and consent to participate**

- 501 All datasets were publicly available, and ethical approval and informed consent were
- 502 acquired for all original studies.

## <sup>504</sup>**Competing interests**

505 The authors declare that they have no conflict of interest.

506













- 
- 
- 619 39. Dinarvand P, Mos<br>620 2019;143(10):1281-1285.<br>621 40. Tang W, Stimson MI<br>622 gene is associated with<br>623 *Haemost.* Feb 2020;18(2)<br>624 41. Manderstedt E, Lind-<br>625 Risk Among Middle-Agec<br>626 *Assoc.* Feb 15 2022;11(
- 
- 621 40. Tang W, Stimson MR, Basu S, et al. Burden of rare e<br>
622 gene is associated with venous thromboembolism: a p<br>
623 *Haemost*. Feb 2020;18(2):445-453. doi:10.1111/jth.14676<br>
624 41. Manderstedt E, Lind-Hallden C, Hal
- 
- 
- 624 Haemost. Feb 2020, Fote), 445-453. doi:10.1111/jth.14676<br>624 41. Manderstedt E, Lind-Hallden C, Hallden C, et al. Clas<br>625 Risk Among Middle-Aged and Older Adults: A Populatior<br>626 *Assoc.* Feb 15 2022;11(4):e023018. d
- 
- 
- Assoc. Feb 15 2022;11(4):e023010: doi:10.11610/Hart 121.023010<br>627 42. Kovács KB, Pataki I, Bárdos H, et al. Molecular characterizatio<br>628 novel p. Ala163Val and p. Ala163Glu mutations causing protein 1<br>629 research: 2015;
- 618 doi:10.1093/harigky1037<br>618 doi:10.1093/harigky1037<br>619 39. Dinarvand P. Moser KA. Protein C Deficiency. Arch Pathol Lab Med Oct<br>620 2019:143(10):1281-1285. doi:10.5858/arpa.2017-0403-RS<br>621 40. Tang W. Stimson MR Basu 626 St. Dinaritan P, Mobil Totel Thomic C Deficiency. 7 Non-Y Laboration Code<br>620 2019:143(10):1281-1285. doi:10.5658/appa.2017-0403-RS<br>621 40. Tang W, Stimson MR. Basu S, et al. Burden of rare exorne sequence variants in 622 gene is associated with venous thromboembolism: a population-based study, *J. Thromb*<br>623 *Haemost* Feb 2020;18(2):445-453. doi:10.1111/jth.14676<br>624 41. Manderstedt E, Lind-Hallden C, Hallden C, et al. Classic Thromb 623 *Haemost* Feb 2020.18(2):445-453. doi:10.1111/jjh.14676<br>623 *Haemost* Feb 2020.18(2):445-453. doi:10.1111/jjh.14676<br>625 Risk Among Middle Aged and Older Adults: A Population-Based Cohort Study. *J Am Heart*<br>626 Risk A 625 Risk Among Middle-Aged and Older Adults: A Population-Based Cohort Study. *J Am Heart*<br>626 Assoc. Feb 15 2022:11(4):e023018. doi:10.1161/JAHA.121.023018<br>627 42. Kovács KB, Palaki I. Bárdos H. et al. Molecular character 626 Risk Among Middle-Aged and Older Adults: Art Cytatalon Based Cohort Clay, 6 Februation<br>626 Assoc Feb 15 2022:11(4):6023018 doi:10.1161/JAHA 121.023018<br>629 Act Risk As. Pataki I, Bárdos H, et al. Molecular characterizat 628 novel p. Alaf 63Val and p. Alaf 63Glu mutations causing protein C deficiency. Thrombosis<br>629 recearch 2015;136(4):718-726.<br>630 43. Wu O, Bayoumi N, Vickers MA, Clark P. ABO(H) blood groups and vascular disease: a<br>631 s
- 
- 629 novel p. Francosca name p. Francosca matarachis stationary protein C democracy. *Thrombosis*<br>629 november, 2015;135(4):718-726.<br>630 43. Wu O. Bayoumi N. Vickers MA Clark P. ABO(H) blood groups and vascular disease: a<br>6 630 43. Wu O, Bayoumi N, Vickers<br>631 systematic review and met<br>632 doi:10.1111/j.1538-7836.2007.02<br>633 44. Li S, Schooling CM. A phen<br>634 Nov 17 2020;18(1):334. doi:10.1<br>635 45. Dennis J, Johnson CY, Ade<br>636 Ser219Gly var
- 
- 
- 633 44. Li S, Schooling CM. A phenome-w<br>634 Nov 17 2020;18(1):334. doi:10.1186/s1.<br>635 45. Dennis J, Johnson CY, Adediran A<br>636 Ser219Gly variant and risk of comme<br>637 analysis of evidence from observatio<br>638 doi:10.1182/b
- 
- 635 45. Dennis J, Johnson CY, Adediran AS, et al. The endo<br>636 Ser219Gly variant and risk of common thrombotic diso<br>637 analysis of evidence from observational studies. *Bloo*<br>638 doi:10.1182/blood-2011-10-383448
- examples and meta-analysis. *J. Thromb Haemost.* Jan. 2008;6(1):62-9.<br>632 doi:10.11111<sub>1</sub>.1538-7836.2007.02818 x<br>633 44. Li S. Schooling CM. A phenome-wide association study of ABO blood groups. *BMC Med*<br>634 Nov 17 2020;1 632 doi:10.1111 $f_1$ 1538-7836.2007.02818.x<br>632 doi:10.1111 $f_1$ 1538-7836.2007.02818.x<br>633 44. Li S. Schooling CM. A phenome-wide association study of ABO blood groups. *BMC Med.*<br>634 Nov 17 2020:18(1):334. doi:10.1186/s12 634 Nov 17 2020;18(1):334. doi:10.1186/s12916-020-01795-4<br>635 45. Dennis J, Johnson CY, Adediran AS, et al. The endothelial protein C receptor (PROCR)<br>636 5er219Gly variant and risk of common thrombotic disorders: a HuGE r Ser219Gly variant and risk of common thrombotic disorders: a HuGE review and meta-<br>analysis of evidence from observational studies. *Blood*. Mar 8 2012;119(10):2392-400.<br>doi:10.1182/blood-2011-10-383448
- examples of evidence from observational studies. *Blood*. Mar 8 2012;119(10):2392-400.<br>638 doi:10.1182/blood-2011-10-383448
- 638 doi:10.1182/blood-2011-10-383448<br>doi:10.1182/blood-2011-10-383448



- 
- 
- 
- 
- 
- 
- 
- 
- external and the metal P, Navarro S, Medina P, Navarro S, Medina P, Navarro S, Medina P, Navarro S, Bonet Juli 2014<br>
641 doi:10.1161/ATVBAHA.113.302518<br>
642 47. Howson JMM, Zhao W, Barnes DR, et al. Fifteen new risk loci f 641 endothelial protein C receptor gene. Functioned Final proteins had been started protein and the 10.1161/ATVBAHA.113.302518<br>642 47. Howson JMM, Zhao W, Bames DR, et al. Fifteen new risk loci for coronary artery<br>643 dise 47. Howson JMM, Zhao W, Barn<br>643 disease highlight arterial-wall-speci<br>644 doi:10.1038/ng.3874<br>645 48. van der Harst P, Verweij N.<br>646 Expanded View on the Genetic Ar<br>647 2018;122(3):433-443. doi:10.1161/C<br>648 49. Kashiwag disease highlight arterial-wall-specific mechanisms. And Genet Jul 2017.49(7):1113-1119.<br>
644 645 48. van der Harst P, Verweij N. Identification of 64 Novel Genetic Loci Provides an<br>
Expanded View on the Genetic Architectu 644 disease highlight arterial wall-specific mechanisms. Nat Genet. Sat Expression First distance has Expanded View on the Genetic Architecture of Coronary Artery Disease. *Circ Res.* Feb 2<br>644 Expanded View on the Genetic 645 48. van der Harst<br>646 Expanded View on t<br>647 2018;122(3):433-443<br>648 49. Kashiwagi M, In<br>649 vulnerability charact<br>650 computed tomograp<br>651 2010;212(1):171-6. d<br>652 50. Tapp LD, Shant:<br>653 subset and monocyte<br>654 J Th 646 Expanded View on the Genetic Architecture of Coronary Artery Disease. *Circ Res.* Feb 2<br>
647 2018;122(3):433-443. doi:10.1161/CIRCRESAHA 117.312086<br>
648 49. Kashiwagi M, Imanishi T, Tsujioka H, et al. Association of m Expanded View on the Genetic Architecture of Generally Futury Disease. Circle Text 2018:122(3):433-443. doi:10.1161/CIRCRESAHA.117.312086<br>
449 Kashiwagi M. Imanishi T. Tsujioka H. et al. Association of monocyte subsets wit 449. Kashiwagi M, Imanishi T, Tsujioka H, et al. Association<br>648 49. Kashiwagi M, Imanishi T, Tsujioka H, et al. Association<br>650 computed tomography in patients with stable angina p<br>465 2010.212(1):171-6. doi:10.1016/j.ath 648 49. Kashiwagi M, Imanishi T, Tsujioka H, et al. Association of monocyte subsets with
- 
- 
- 
- 
- 
- 
- 650 computed tomography in patients with stable angina pedoris. *Atherosclerosis*. Sep<br>
861 2010;212(1):171-6. doi:10.1016/j.atherosclerosis.2010.05.004<br>
862 50. Tapp LD, Shantslia E, Wrigley BJ, Pamukcu B, Lip GY. The CD1 661 computed tomography in patients with stable angina pectoric. Atheretical computed to the 2010.212(1):171-6. doi:10.1016/j atherosclerosis.2010.05.004<br>652 60. Tapp LD, Shantisla E, Wrigley BJ, Pamukeu B, Lip GY. The CD1 EXAMPLE PROP LD, Shantsila E, Wrigley BJ, Pamukcu B, Lip GY.<br>652 subset and monocyte-platelet interactions in patients with ST-<br>654 J Thromb Haemost. Jul 2012;10(7):1231-41. doi:10.1111/j.153<br>655 51. Anker SD, Egerer Kr Fa 653 subset and monocyte-platelet interactions in patients with ST-elevation myocardial infarction.<br>654 J Thromb Haemost Jul 2012;10(7):1231-41. doi:10.1111/j.1538-7836.2011.04603.x<br>655 51. Anker SD, Egerer Kr Fau - Volk HD 654 *J. Thromb Haemost.* Jul 2012;10(7):1231-41. doi:10.1111/j.1538-7836.2011.04603.x<br>655 51. Anker SD, Egerer Kr Fau - Volk HD, Volk Hd Fau - Kox WJ, Kox Wj Fau - Poole-Wilson<br>656 PA, Poole-Wilson Pa Fau - Coats AJ, Coats 655 51. Anker SD, Egerer Kr Fau - Volk HD, Volk Hd Fau - Kox WJ, Kox Wj Fau - Poc<br>656 PA, Poole-Wilson Pa Fau - Coats AJ, Coats AJ. Elevated soluble CD14 receptors are<br>657 cytokines in chronic heart failure. (0002-9149 (Pr 656 PA, Poole-Wilson Pa Fau - Coats AJ, Coats AJ. Elevated soluble CD14 receptors and altered<br>657 cytokines in chronic heart failure. (0002-9149 (Print))<br>658 52. Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune act cytokines in chronic heart failure. (0002-9149 (Print))<br>658 52. Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart<br>659 failure: a prospective cohort study. *Lancet*. May 29 1999;353(9167):
- 
- 658 52. Niebauer J, Volk HD, Kemp M, et al. Endotoxin<br>659 failure: a prospective cohort study. *Lancet.*<br>660 doi:10.1016/S0140-6736(98)09286-1
- 659 failure: a prospective cohort study. *Lancet*. May 29 1999;353(9167):1838-42.<br>660 doi:10.1016/S0140-6736(98)09286-1 660 doi:10.1016/S0140-6736(98)09286-1<br>doi:10.1016/S0140-6736(98)09286-1
- 660 doi:10.1016/S0140-6736(98)09286-1



- 684 61. Knox C,<br>685 2024. *Nucleic*<br>686 62. Zhou Y,<br>687 druggability<br>688 doi:10.1093/n<br>689<br>690
- 
- 
- 1. Microsoftextual interaction of the Drugbank M, Microsoftextual interactions and the Drugbank Acids Res. Jan 5. 2024;52(D1):D1265-D1275. doi:10.1093/mar/gkad761<br>685 62. Zhou Y. Zhang Y. Zhao D. et al. TTD: Therapeutic Ta 686 62. Zhou Y. Zhang Y. Zhao D. et al. TTD: Therapeutic Target Database describing<br>686 62. Zhou Y. Zhang Y. Zhao D. et al. TTD: Therapeutic Target Database describing<br>687 doi:10.1093/nar/gkad751<br>689<br>699 687 druggability information. *Nucleic Acids Res.* Jan 5 2024;52(D1):D1465-D1477.<br>686 doi:10.1093/nar/gkad751<br>689<br>690 688 doi:10.1093/haifgkad751<br>688 doi:10.1093/haifgkad751<br>689
- 689<br>689<br>690

689

## <sup>691</sup>**Figure Legends**



699

## <sup>700</sup>**Figure 2. Result of the PWAS**

<sup>701</sup>**A.** Manhattan plot for the PWAS of CVD. Each dot represents the correlation between <sup>702</sup>a disease and a gene, with the x-axis indicating genomic location and the y-axis 703 showing  $-log_{10}(P)$ . The gray horizontal line represents the Bonferroni-corrected 704 significant threshold,  $P < 2.92 \times 10^{-5}$ . The significant results of the three categories 705 diseases are shown in red, green, blue, respectively. The labeled genes are the most 706 significant results on each chromosome

<sup>707</sup>**B.** The number of significant genes in PWAS for 26 CVD diseases. Different colors 708 represent different disease categories. 27 jointly significant genes dropped by 709 conditional analysis (gray).

710 C. Regional association of PWAS hits in conditional analysis for heart failure. 711 Conditionally significant proteins are CELSR2, GSTM1, SPINK8, DAG1, HYAL1, <sup>712</sup>FABP2, ACYP1, FES, GSTT2B and SUSD2. Top panel in each plot highlights the <sup>713</sup>marginally associated PWAS genes (blue) and the jointly significant genes (green).

- <sup>714</sup>Bottom panel shows a regional Manhattan plot of the data before (grey) and after
- <sup>715</sup>(blue) conditioning on the predicted expression of the green genes. Chr: chromosome.
- 716

#### <sup>717</sup>**Figure 3. Results for the causal genes.**

- <sup>718</sup>**A.** The heatmap presents whole PWAS results for 94 genes passing causality tests and
- 719 color depth reflects the association direction and magnitude. Genes identified in
- 720 replication PWAS are represented by circles in the heatmap. Causal genes are labeled
- 721 "\*" and the novel gene with no significant variant  $(P < 5 \times 10^{-8})$  within  $\pm 2M$  window
- 722 of the gene range in GWAS results are labeled in red.
- <sup>723</sup>**B.** The Venn diagram illustrates the overlap of causal genes across three disease 724 categories.
- 725 C. The number of novel genes in different diseases.

726 D. The top Manhattan plot represents the pQTL and the GWAS results within the <sup>727</sup>*PROC* genomic region for venous thromboembolism. The bottom Manhattan plot 728 represents the pQTL and the GWAS results within the *FN1* genomic region for 729 coronary heart disease and coronary atherosclerosis.

730

## <sup>731</sup>**Figure 4. Function annotation of the identified genes**

<sup>732</sup>**A.** The significant enriched Gene Ontology (GO) biological process (BP) terms of the <sup>733</sup>causal genes in different categories. The color of the bar represents the biological 734 function category to which the pathway belongs. Immunity/inflammation (light coral),

<sup>735</sup>lipid-related process (faint yellow), vessel/blood-related process (purple) and other 736 (gray).

<sup>737</sup>**B.** The network constructed with identified causal genes. Lines represent a physical 738 interaction, and line thickness is proportional to the interaction score. Genes 739 associated with cardiac disease, venous disease and cerebrovascular disease are 740 shown in red, green, and blue, respectively. Genes with more connections are shown 741 with larger size. Community 1 include 16 proteins associated with 742 immunity/inflammation. Community 2 include 6 proteins associated with lipid-related 743 process. Community 3 include 6 proteins associated with vessel/blood-related process, 744 especially the formation of fibrin clot.

C. The significant enrichment results of mouse phenotypes of the causal genes in 746 different categories. The color of the bar represents the biological function category to which the pathway belongs. Immunity/inflammation (light coral), lipid-related process (faint yellow), vessel/blood-related process, (purple) and other (gray).

749 D. Results of the longitudinal stability analysis at the protein level (left) and single-750 cell level (right). At the protein level, genes are classified as stable (blue) or variable <sup>751</sup>(red) based on a coefficient of variation (CV) threshold of 10%. Among the 94 causal 752 genes, 37 genes were identified as stable. The color blocks on the left indicate the 753 relevant grouping of the genes in the PWAS results. At the single-cell level, the 754 threshold is set at 10%, with gray representing samples with low average expression 755 (average expression  $< 0.01$  after normalization). 24 genes exhibit stable expression 756 across 19 cell types. Different donors are indicated by different colors.

- <sup>757</sup>**E.** The constructed gene-drug-disease network of causal genes. The colors of the lines
- 758 in the network signify the category of genes. ICD: International Classification of

- 
- 761

<sup>759</sup> Diseases.

## **Gene replicated causal PHE**  ABO Both Both Pulmonary embolism Both COLOC Deep Venous Thrombosis, Venous Thromboembolism INTERVAL Both Large artery stroke INTERVAL COLOC Myocardial infarction, Any stroke, Cardioembolic stroke ANGPTL3 ARIC COLOC Statin medication ASPN Both Both Venous Thromboembolism CCDC134 Both Both Atrial fibrillation CD4 INTERVAL SMR Coronary atherosclerosis COL15A1 Both SMR Atrial fibrillation COL6A3 Both Both Heart failure CTSB INTERVAL COLOC Calcific aortic valvular stenosis DLK1 INTERVAL COLOC Diseases of veins DUSP13 INTERVAL Both Atrial fibrillation ECM1 ARIC COLOC Hypertension EPHA2 Both Both Statin medication F10 Both Both Pulmonary embolism<br>Both COLOC Venous Thromboemb Venous Thromboembolism F11 ARIC Both Deep Venous Thrombosis, Diseases of veins, Any stroke, Cardioembolic stroke<br>ARIC COLOC Venous Thromboembolism. Pulmonary embolism Venous Thromboembolism, Pulmonary embolism F2 Both Both Venous Thromboembolism, Pulmonary embolism<br>Both SMR Deep Venous Thrombosis. Diseases of veins Deep Venous Thrombosis, Diseases of veins FABP2 ARIC SMR Hypertension, Heart failure, Coronary revascularization FN1 ARIC Both Heart failure, Coronary Heart Disease, Angina pectoris ARIC COLOC Myocardial infarction, Coronary atherosclerosis, Coronary revascularization, Coronary artery bypass grafting GAS6 ARIC COLOC Statin medication GSTT2B INTERVAL SMR Heart failure IL1RN Both SMR Myocardial infarction IL6R Both Both Aortic aneurysm, Coronary Heart Disease, Coronary atherosclerosis, Angina pectoris, Coronary angioplasty Both COLOC Coronary revascularization, Coronary artery bypass grafting Both SMR Atrial fibrillation, Heart failure INHBB ARIC Both Coronary artery bypass grafting<br>Both COLOC Statin medication Statin medication INHBC ARIC Both Heart failure ITIH3 ARIC SMR Heart failure KLB ARIC SMR Statin medication LRIG1 ARIC Both Atrial fibrillation MMP12 Both Both Any stroke<br>Both COLOC Large arter Large artery stroke NRP1 Both SMR Coronary Heart Disease NUDT5 ARIC SMR Statin medication, Heart failure PCSK9 ARIC Both Heart failure ARIC COLOC Statin medication, Myocardial infarction, Coronary Heart Disease, Coronary atherosclerosis, Angina pectoris, Coronary revascularization, Coronary angioplasty, Coronary artery bypass grafting, Valvular heart disease, Diseases of arteries and

#### 762 Table1. Summary of the 34 replicable CVD causal genes.



# **1. Discovery plasma proteome-wide association study (PWAS) analysis**





# **3. Function verification of candidate causal genes**







**Cardiac disease Communist Cerebrovascular disease** 





